This record was last updated December 16, 2024 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a multicenter, open-label, phase II study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activities of AK104，a PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line therapy in subjects with advanced unresectable or metastatic pancreatic ductal adenocarcinoma.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2023-05-05.
Status change: Not Yet Recruiting → Recruiting2024-12-11